| Literature DB >> 34218774 |
Md Mominur Rahman1, Muniruddin Ahmed1, Mohammad Touhidul Islam1, Md Robin Khan2, Sharifa Sultana1, Saila Kabir Maeesa1, Sakib Hasan1, Md Abid Hossain1, Kazi Sayma Ferdous1, Bijo Mathew3, Abdur Rauf4, Md Sahab Uddin5,6.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus responsible for the current global pandemic, which first emerged in December 2019. This coronavirus has affected 217 countries worldwide, most of which have enacted non-remedial preventive measures, such as nationwide lockdowns, work from home, travel bans, and social isolation. Pharmacists, doctors, nurses, technologists, and other healthcare professionals have played pivotal roles during this pandemic. Unfortunately, confirmed drugs have not been identified for the treatment of patients with coronavirus disease 2019 (COVID-19) caused by SARSCoV2; however, favipiravir and remdesivir have been reported as promising antiviral drugs. Some vaccines have already been developed, and vaccination is ongoing globally. Various nanotechnologies are currently being developed in many countries for preventing SARS-CoV-2 spread and treating COVID-19 infections. In this article, we present an overview of the COVID-19 pandemic situation and discuss nanotechnology-based approaches and investigational therapeutics for COVID-19. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: COVID-19; SARS-COV-2; antiviral drugs; immunomodulation; nanotechnology; vaccines
Mesh:
Substances:
Year: 2022 PMID: 34218774 DOI: 10.2174/1381612827666210701150315
Source DB: PubMed Journal: Curr Pharm Des ISSN: 1381-6128 Impact factor: 3.310